

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Transcenta Holding Limited

創勝集團醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6628)

CHANGE OF AUDITOR

This announcement is made by Transcenta Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

RESIGNATION OF AUDITOR

The board of directors (the “**Directors**”) of the Company (the “**Board**”) announces that Deloitte Touche Tohmatsu (“**Deloitte**”) has resigned as the auditor of the Company with effect from November 12, 2025 as the Company and Deloitte could not reach a consensus on the proposed audit fee in respect of the audit of the consolidated financial statements of the Group for the financial year ending December 31, 2025.

The audit committee of the Company (the “**Audit Committee**”) has reviewed the audit fee proposal provided by Deloitte as well as that of other professional accounting firms, and has taken into consideration their respective experience, resource allocation and proposed fee for the year ending December 31, 2025. In view of the more competitive proposal provided by the other professional accounting firm, the Board, with the recommendation of the Audit Committee, is satisfied that a change of auditor would better achieve the Company’s cost-control objectives and is in the interests of the Company and the shareholders of the Company (the “**Shareholders**”) as a whole.

Deloitte has confirmed in writing that, save as disclosed above, there are no circumstances connected with its resignation that need to be brought to the attention of the Shareholders. The Board and the Audit Committee have also confirmed that, other than the above fee matter, there is no disagreement between the Company and Deloitte, and no other matters in respect of the resignation that need to be brought to the attention of the Shareholders.

As at the date of this announcement, Deloitte has not commenced any review or audit work on the Group’s consolidated financial statements for the year ending December 31, 2025. The Board believes that the change of auditor will not have any material impact on the Group’s annual audit and release of financial results for the year ending December 31, 2025.

The Board would like to express its sincere gratitude to Deloitte for its professional services rendered to the Group during its tenure of office.

APPOINTMENT OF AUDITOR

Following the resignation of Deloitte, the Board, with the recommendation of the Audit Committee, has resolved to appoint Ernst & Young (“EY”) as the new auditor of the Company with effect from November 12, 2025 to fill the casual vacancy and to hold office until the conclusion of the next annual general meeting of the Company.

In assessing the appointment of EY, the Audit Committee has taken into account, among other things, (i) market reputation and track record; (ii) industry knowledge and technical competence; (iii) resources and timing (including manpower); (iv) independence and objectivity; (v) proposed audit approach and fee; (vi) the relevant guidelines issued by the Accounting and Financial Reporting Council. Based on the above, the Audit Committee considers EY independent, competent and capable of performing a high-quality audit within the required timeframe, and that the proposed fee is commensurate with the extent of audit work required.

The Board and the Audit Committee are of the view that the change of auditor is in the interest of the Company and the Shareholders as a whole as it would maintain audit quality while enhancing the cost-effectiveness and efficiency of the Company’s annual audit.

The Board would like to take this opportunity to express its warm welcome to EY on its appointment.

By order of the Board
Transcenta Holding Limited
Xueming Qian
*Executive Director, Chairman and
Chief Executive Officer*

Hong Kong, November 12, 2025

As at the date of this announcement, the Board comprises Dr. Xueming Qian as executive Director, chairman and chief executive officer, Dr. Li Xu as non-executive Director and Mr. Jiasong Tang, Mr. Zhihua Zhang, Dr. Kumar Srinivasan and Ms. Helen Wei Chen as independent non-executive Directors.